A PHASE II OPEN LABEL, RANDOMIZED NON-COMPARATIVE TRIAL OF NIVOLUMAB ALONE OR IN COMBINATION WITH IPILIMUMAB FOR THE TREATMENT OF PATIENTS WITH ADVANCED HYPERMUTATED SOLID TUMORS DETECTED BY A BLOOD BASED ASSAY- Nivolumab Ipilimumab in Patients with HyperMutated Cancers Detected in BLood (NIMBLe)
Study of Nivolumab Alone or in Combination with Ipilimumab for the Treatment of Patients with Advanced Hypermutated Solid Tumors
Sponsor: Canadian Cancer Trials Group
Enrolling: Male and Female Patients
IRB Number: AAAR9508
U.S. Govt. ID: NCT03461952
Contact: Research Nurse Navigator: 212-342-5162 / cancerclinicaltrials@cumc.columbia.edu
Additional Study Information: The purpose of this study is to find out what effects nivolumab or nivolumab given in combination with ipilimumab have on you and your cancer given the presence of genetic biomarkers (POLE and POLD1). This study will also look at the side effects of these two new immunotherapy drugs.
This study is closed
Investigator
Do You Qualify?
Are you 18 years of age or older? Yes No
Do you have an advanced solid tumor? Yes No
Submit
Cancel
You may be eligible for this study

Place Holder



Cancel
For more information, please contact:
Research Nurse Navigator
cancerclinicaltrials@cumc.columbia.edu
212-342-5162
This website uses cookies as well as similar tools and technologies to understand visitors’ experiences. By continuing to use this website, you consent to Columbia University’s usage of cookies and similar technologies, in accordance with the Columbia University Website Cookie Notice.
I AGREE